Global Pneumococcal Infections Pipeline Insight Market Report 2021: Challenges and Opportunities that Could Influence R&D – ResearchAndMarkets.com

Global Pneumococcal Infections Pipeline Insight Market Report 2021: Challenges and Opportunities that Could Influence R&D – ResearchAndMarkets.com




Global Pneumococcal Infections Pipeline Insight Market Report 2021: Challenges and Opportunities that Could Influence R&D – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Pneumococcal Infections – Pipeline Insight, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This Pneumococcal infections – Pipeline Insight, 2021 report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Pneumococcal infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Pneumococcal infections R&D. The therapies under development are focused on novel approaches to treat/improve Pneumococcal infections.

Pneumococcal infections Emerging Drugs Chapters

This segment of the Pneumococcal infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Pneumococcal infections Emerging Drugs

20-Valent Pneumococcal Conjugate Vaccine: Pfizer

On September 20, 2018, Pfizer announced the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for 20vPnC for the prevention of invasive disease and pneumonia in adults age 18 years or older. The 20vPnC vaccine candidate consists of capsular polysaccharide conjugates for the 13 serotypes included in Prevnar 13 (Pfizer), along with 7 additional serotypes that cause invasive pneumococcal disease.

The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for the 20-valent pneumococcal conjugate vaccine (20vPnC) candidate (Pfizer) for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes in adults aged 18 years and older.

V 114: Merck sharp & Dohme

V114 is Merck’s investigational 15-valent pneumococcal conjugate vaccine candidate for the prevention of invasive pneumococcal disease in adults. V114 consists of pneumococcal polysaccharides from 15 serotypes conjugated to a CRM197 carrier protein and includes serotypes 22F and 33F, which are commonly associated with invasive pneumococcal disease. V114 previously received Breakthrough Therapy Designation from the FDA for the prevention of invasive pneumococcal disease in pediatric patients 6 weeks to 18 years of age and adults 18 years of age and older.

The U.S. Food and Drug Administration (FDA) accepted for priority review a Biologics License Application (BLA) for V114, Merck’s investigational 15-valent pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease in adults 18 years of age and older. The European Medicines Agency is also reviewing an application for licensure of V114 in adults.

Pneumococcal infections: Therapeutic Assessment

Major Players in Pneumococcal infections

There are approx. 15+ key companies which are developing the therapies for Pneumococcal infections. The companies which have their Pneumococcal infections drug candidates in the most advanced stage, i.e. Preregistration include, Pfizer.

Phases

This report covers around 15+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Pneumococcal infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Pneumococcal infections: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pneumococcal infections therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pneumococcal infections drugs.

Pneumococcal infections Report Insights

  • Pneumococcal infections Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Pneumococcal infections Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Pneumococcal infections drugs?
  • How many Pneumococcal infections drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pneumococcal infections?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Pneumococcal infections therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Pneumococcal infections and their status?
  • What are the key designations that have been granted to the emerging drugs?

Companies Mentioned

  • GlaxoSmithKline
  • Gangagen
  • CanSino Biologics Inc.
  • Pfizer
  • Merck Sharp & Dohme
  • Beijing Zhifei Lvzhu Biopharmaceutical
  • SK Chemicals Co., Ltd.
  • LG Life Sciences
  • Astellas Pharma
  • EuBiologics Co.,Ltd
  • Affinivax
  • ImmunoBiology

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/a831m7

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900